Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice-Reference-Cited by-同舟云学术

Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice

Published:2018-07 Issue:1 Volume:84 Page:64-77
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

McLoughlin Hayley S.¹^ORCID,Moore Lauren R.¹,Chopra Ravi¹,Komlo Robert¹,McKenzie Megan¹,Blumenstein Kate G.¹,Zhao Hien²,Kordasiewicz Holly B.²,Shakkottai Vikram G.¹,Paulson Henry L.¹

Affiliation:

1. Department of Neurology; University of Michigan; Ann Arbor MI

2. Ionis Pharmaceuticals; Carlsbad CA

Funder

Ionis Pharmaceuticals

Michigan Brain Initiative Predoctoral Fellowship for Neuroscience

Becky Babcox Fund Pilot Research Award

National Institute of Neurological Disorders and Stroke

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ana.25264/fullpdf

Reference50 articles.

1. Toward understanding Machado-Joseph disease;Costa Mdo;Prog Neurobiol,2012

2. Survival and severity in dominant cerebellar ataxias;Monin;Ann Clin Transl Neurol,2015

3. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7;Rüb;Prog Neurobiol,2013

4. Machado-Joseph disease: an autosomal dominant motor system degeneration;Rosenberg;Mov Disord,1992

5. Polyglutamine spinocerebellar ataxias-from genes to potential treatments;Paulson;Nat Rev Neurosci,2017

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal Changes of Clinical, Imaging, and Fluid Biomarkers in Preataxic and Early Ataxic Spinocerebellar Ataxia Type 2 and 7 Carriers;Neurology;2024-09-10

2. Genetic Interventions for Spinocerebellar Ataxia and Huntington’s Disease: A Qualitative Study of the Patient Perspective;Journal of Huntington's Disease;2024-09-10

3. Insight into the early pathogenesis and therapeutic strategies of spinocerebellar ataxia type 3/machado–joseph disease from mouse models;Parkinsonism & Related Disorders;2024-09

4. CAG repeat-selective compounds reduce abundance of expanded CAG RNAs in patient cell and murine models of SCAs;2024-08-17

5. ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice;Molecular Therapy;2024-05